Yuekang Pharmaceuticals: Subsidiary YKYY033 Injection Received Clinical Trial Approval from National Medical Products Administration.

Yuekang Pharmaceutical announced that its subsidiaries Yuekang Innovation and Hangzhou Tianlong recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the YKYY033 injection used for elective hip or knee replacement surgery in adult patients to prevent the formation of venous thrombosis. The company will conduct phase I clinical trials for this product. The drug was accepted on May 21, 2026, meets the relevant requirements for drug registration, and is approved for clinical trials.